Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation
8.3
来源：
Nature
关键字：
PROTAC
发布时间：
2025-11-29 03:57
摘要：
D16-M1P2, a novel bifunctional PROTAC targeting PKMYT1, was developed using an AI-driven generative platform. It exhibits dual mechanisms of action, effectively degrading and inhibiting PKMYT1, leading to significant antitumor responses in xenograft models. The compound shows high selectivity and favorable pharmacokinetic properties, indicating its potential as a therapeutic agent for cancers with specific genetic alterations. This research underscores the promise of AI in drug discovery and the development of targeted cancer therapies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.8分+0.8分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
D16-M1P2 demonstrates dual mechanisms of PKMYT1 degradation and inhibition.
The PROTAC shows robust antitumor response in xenograft models.
AI-driven platform utilized for the discovery of novel PKMYT1 inhibitors.
真实性检查
否
AI评分总结
D16-M1P2, a novel bifunctional PROTAC targeting PKMYT1, was developed using an AI-driven generative platform. It exhibits dual mechanisms of action, effectively degrading and inhibiting PKMYT1, leading to significant antitumor responses in xenograft models. The compound shows high selectivity and favorable pharmacokinetic properties, indicating its potential as a therapeutic agent for cancers with specific genetic alterations. This research underscores the promise of AI in drug discovery and the development of targeted cancer therapies.